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Randomized Controlled Trial of Bisacodyl
Suppository Versus Placebo for Postoperative Ileus
After Elective Colectomy for Colon Cancer
Sukanya Wiriyakosol, Youwanuch Kongdan, Chakrapan Euanorasetr, Noppadol Wacharachaisurapol1 and
Panuwat Lertsithichai, Department of Surgery, Faculty of Medicine, and 1Pharmacy Service, Ramathibodi 
Hospital and Medical School, Mahidol University, Bangkok, Thailand.
OBJECTIVE: To compare the use of bisacodyl suppository with placebo in resolving postoperative ileus
after elective colectomy in a randomized controlled trial.
METHODS: Twenty elective colectomy patients were randomized to receive either bisacodyl or placebo
suppository on the third postoperative day. Outcomes included time to first defaecation, length of hospital
stay, and postoperative complications. Participants and the primary investigator were unaware of the treat-
ment assignment.
RESULTS: All 10 participants in the bisacodyl group defaecated on the third postoperative day, while
participants in the placebo group defaecated on days 3 (2/10), 4 (5/10) and 5 (3/10) (p < 0.001). The average
lengths of hospital stay for the bisacodyl and placebo groups were 8.5 ± 2.7 days and 10.4 ± 5.3 days,
respectively (p = 0.325). No significant complications occurred in either group.
CONCLUSION: Bisacodyl suppository seems to be effective and safe in resolving postoperative ileus
after elective colectomy in colon cancer patients. [Asian J Surg 2007;30(3):167–72]
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Introduction
Postoperative ileus is usually defined as a transient
impairment of gastrointestinal (GI) motility occurring
after surgery and is characterized by abdominal distension,
lack of bowel sounds and delayed passage of gas and
stool.1–3 Since postoperative ileus almost always occurs
after major abdominal surgery, this condition is sometimes
considered a normal response to surgical trauma. None-
theless, hastening the resolution of ileus might shorten
hospital stay and save hospital costs without increasing
and perhaps even reducing postoperative morbidity.1 This
may be especially pertinent for patients undergoing 
colorectal surgery, where the return of colonic function 
is usually slower than the rest of the GI tract and may be
delayed for 3–5 days.1,4
Many methods have been used to hasten the resolution
of postoperative ileus.1–3 Few studies have addressed the
use of rectal suppository laxatives, however.1,5 The use of
suppository (contact stimulant) laxatives has the advan-
tage of requiring minimal effort on the patient’s part, but
may adversely affect anastomotic healing due to the vigor-
ous stimulation of bowel movement. A review of 24 patients
undergoing elective colectomy at Ramathibodi Hospital
in 2003 found that six patients had been treated with
bisacodyl suppository. None of these patients had com-
plications attributed to the use of the suppository. One
non-randomized study compared the use of bisacolic 
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suppository (in addition to oral milk of magnesia) with
no laxatives in patients undergoing radical hysterectomy,
and found more rapid recovery of bowel function for the
former.5 No complications were observed with the use of
bisacolic. However, no randomized controlled studies have
been published. The aim of the present study was to com-
pare the use of bisacodyl suppository with placebo in 
a randomized clinical trial, in terms of time to return of
normal bowel function and postoperative complications, in
patients with colon cancer undergoing elective colectomy.
Patients and methods
A double-blind, randomized, placebo-controlled clinical
trial was performed to assess the efficacy of bisacodyl 
suppository in hastening the resolution of postoperative
ileus following elective colectomy in patients with colon
cancer. During the 12-month period between January 
and December 2005, patients undergoing elective colec-
tomy for colon cancer in the Department of Surgery,
Ramathibodi Hospital, were eligible for participation.
Inclusion criteria included: age > 18 years; American
Society of Anesthesiologist (ASA) classes I to III; failure to
defaecate on the third postoperative day. Rectal supposi-
tory used to stimulate bowel function was considered on
the third day after surgery because most surgeons in our
institution felt that it might be unnecessary or unsafe to
provide suppositories prior to that time. Exclusion criteria
included: evidence of colonic obstruction; carcinomatosis
peritonei; refusal to participate.
The primary outcome was the time to defaecation,
measured in days, from the day of the primary operation
to the first observed passage of stool. Secondary outcomes
included the time to audible bowel sounds, defined as the
first detection of audible bowel sounds on auscultation,
measured from the day of operation; time to flatus, in
days, measured similarly but where flatus was defined as
passing of bowel gas as reported by the patient; and
length of hospital stay, in days. Other outcomes included
the number of suppositories provided, time to resumption
of oral soft diet, in days, and any observed postoperative
complications. These outcomes were recorded and meas-
ured by the primary investigator (SW).
Baseline data collected included age, gender, diagnosis,
staging of cancer, ASA class and serum potassium level
prior to the use of rectal suppository. Treatment-related
data included type of operation, operative time, amount
of blood loss, types of postoperative analgesics and doses of
opioids used.
From a review of a series of 24 elective colectomy
patients treated at Ramathibodi Hospital in 2003, the aver-
age time to defaecation (for those not treated with bisacodyl
suppository) was 5.2 ± 1.3 days. It was hypothesized that
bisacodyl suppository given on day 3 after operation would
reduce the average time to defaecation by 2 days. To detect
this difference with a type I error of 0.05 and a power of
0.9, a sample size of 10 patients per group or 20 patients
overall was needed.
Participants were randomized using a computer in
blocks of 2 and 4 to one of the two treatment groups.
Randomization and allocation sequence were assigned by
the statistician (PL) and concealment of allocation was
done using sealed opaque envelopes. Research nurses in
each ward opened the envelopes on the third postoperative
day and assigned participants to their treatment groups,
where participants in the treatment group received 10 mg
bisacodyl suppository (Dulcolax®; Boehringer Ingelheim
GmbH, Ingelheim, Germany) and those in the control
group received placebo suppository. The placebo sup-
pository was manufactured at the Faculty of Pharmacy,
Mahidol University, to have the consistency and appear-
ance of the bisacodyl suppository. The patient-participants
and the primary investigator were unaware of the treatment
assignment.
All patients received the same standard preoperative
bowel preparation with oral sodium phosphate solution.
All patients underwent the same postoperative early ambu-
lation programme. Nasogastric tubes were removed within
24 hours after operation. Patients were usually given mor-
phine sulfate for analgesia. Some also received intravenous
parecoxib or pethidine if they could not tolerate the side
effects of morphine. No gum chewing was allowed.
If a patient did not spontaneously defaecate on the
third day after surgery, s/he was approached by the pri-
mary investigator for consent to participate in the research
study. If consent was given, a first suppository was applied.
If the participant did not defaecate after 12 hours, a sec-
ond suppository, identical to the first, was applied. After
the second suppository, no more were given (Figure). All
participants resumed oral intake after defaecation and
were followed until hospital discharge.
Note that most surgeons in the study hospital allowed
resumption of oral diet according to a fixed protocol,
regardless of when defaecation occurred. For this group
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of surgeons, all patients were allowed liquid diet on the
fifth day after surgery, and soft diet 1 day later, if no com-
plications were suspected by that time. Hence, the time to
resumption of oral diet was not a sensitive indicator of
the return to normal bowel function in this study.
The study protocol was approved by the hospital’s
ethics review committee. All participants gave informed
consent prior to enrollment into the study.
Continuous data were summarized as mean (standard
deviation) or median (range), and categorical and ordinal
data were summarized as counts and percentages. Analysis
was done according to the intention-to-treat principle.
Statistical tests were performed using t test or Wilcoxon
rank sum test as appropriate for continuous and ordinal
variables, and χ2 or Fisher’s exact test as appropriate for
categorical variables. Correlation between variables not
normally distributed was measured using Spearman’s rank
correlation. Statistical significance was defined as a p value
of 0.05 or less. STATA version 7 (Stata Corp., College
Station, TX, USA) was used for all statistical analyses.
Results
A total of 20 patients were approached and all consented
to participate in the research during the study period. Ten
participants received bisacodyl suppository and 10 received
the placebo. The flow of patients is illustrated in the
Figure. All patients underwent treatment as assigned 
with no loss to follow-up. Two participants in the control
group required a third therapeutic (bisacodyl) suppository
on the sixth and eighth postoperative days for abdominal
bloating after oral feeding, which occurred after the first
defaecation episodes.
Baseline and demographic data are presented in Table 1.
These data were comparable between the two treatment
groups, with the important exception of the amount of
morphine used. A clinically significant larger amount of
morphine was used in the control group compared with
the suppository group, about twice as much, although this
was only marginally statistically significant because of the
small sample size (Wilcoxon rank sum test, p = 0.053).
Although two patients in the suppository group and one
in the control group had laparoscopic-assisted colorectal
procedures, these patients were part of a “learning curve”
experience.
The outcomes of the study are presented and contrasted
on an intention-to-treat basis between the two groups in
Table 2. The most obvious differences were the timing
(day) of defaecation and the number of suppositories
used. All participants receiving bisacodyl suppository
defaecated on the same day of application, while most
patients receiving placebo defaecated 1 or 2 days later. Most
participants in the bisacodyl group (90%) received only one
suppository. There was no significant difference between
the two groups in terms of the time to resumption of oral
soft diet.
There was no significant correlation between the
amount of morphine used and days to defaecation. The
median amounts of morphine used for patients defaecating
on days 3, 4 and 5 were 15 mg, 43 mg and 23 mg, respec-
tively. The correlation coefficient for days to defaecation
and amount of morphine used was 0.256 (p = 0.322).
There was only a weak correlation between the amount of
morphine used and duration of hospital stay (r = 0.342;
p = 0.179).
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Placebo group
(n = 10)
First suppository
Bisacodyl group
(n = 10)
First suppository
Postoperative ileus – third day
Defaecation
Enrollment and randomization 
(n = 20) 
Yes No (in 12 hours)
Start oral feeding
Completed trial
(n = 20)
Second suppository
Yes No
Defaecation
Await
defaecation
Start oral feeding
Figure. Trial flow diagram.
Only two postoperative complications occurred in this
study, both in the placebo group. These were all superfi-
cial surgical site infections. No anastomotic complications
occurred. All participants in the bisacodyl group were able
to tolerate oral diet after defaecation. Four participants in
the placebo group could not tolerate oral diet after defae-
cation, and two of these eventually required supplemental
bisacodyl suppositories because of persistent abdominal
bloating and discomfort.
The average length of hospital stay was 2 days shorter
in the bisacodyl group (8.5 vs. 10.4 days, a difference of 
1.9 days; 95% confidence interval, −2.0 to 5.8 days), but
this difference did not reach statistical significance (t test,
p = 0.325).
Discussion
The results of this study showed that defaecation occurred
significantly earlier in the group that received bisacodyl
suppository, without evident anastomotic complications.
Participants in the bisacodyl group were also able to bet-
ter tolerate oral diet, and were able to leave the hospital 
2 days earlier on average, which is a clinically important
result. However, the latter difference was not statistically
significant.
An unexpected finding was that patients in the con-
trol group received twice the amount of morphine as the
suppository group. We were unable to find any systematic
explanation for this result. Because of the small sample
size, this might have been a chance occurrence. Nonetheless,
the larger amount of morphine provided to the control
group might confound the association between the use of
bisacodyl suppository and earlier defaecation. Although
this might have been the case, on closer analysis, there 
was no clear correlation between days to defaecation and
amount of morphine used. This lack of correlation
implied that the amount of morphine used was unlikely
to explain all the association between the use of bisacodyl
suppository and earlier defaecation. Similarly, the larger
amount of morphine used might have delayed hospital
stay, but probably not by much, since this correlation was
also weak.
The pathogenesis of postoperative ileus is incom-
pletely understood.1–3 Neural, hormonal, pharmacological
and inflammatory mechanisms, as well as fluid and elec-
trolyte imbalances, all have plausible roles in creating and
maintaining the condition.1–3,6 Postoperative ileus is cur-
rently believed to be unnecessary for optimal postopera-
tive recovery, and if prolonged can result in increased
complications and costs.1 Treatment modalities targeted
at various potential mechanisms have been met with
some success, such as the use of laparoscopic surgery,7,8
thoracic epidural anaesthesia,9,10 early feeding (less clear
benefit),11 gum chewing,4,12,13 the use of certain promotility
drugs,2,14,15 and combinations of the above (multimodality
approach).16,17
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Table 1. Baseline and demographic variables in the control
(n = 10) and treatment (n = 10) groups*
Base line variables Control group Treatment group
Age (yr) 59.9 ± 12.4 63.8 ± 8.1
Sex (female:male) 4:6 (40:60) 5:5 (50:50)
Location of tumour
Right side of colon 4 (40) 3 (30)
Left side of colon 1 (10) 1 (10)
Sigmoid colon 5 (50) 6 (60)
Operation
Right hemicolectomy 4 (40) 3 (30)
Left hemicolectomy 1 (10) 1 (10)
Sigmoidectomy 5 (50) 6 (60)
TNM staging
Stage I 1 (10) 2 (20)
Stage II 5 (50) 5 (50)
Stage III 4 (40) 3 (30)
ASA class
ASA II 9 (90) 8 (80)
ASA III 1 (10) 2 (20)
Operation type
Open 9 (90) 8 (80)
Laparoscopic 1 (10) 2 (20)
Analgesia (intravenous)
Morphine 8 (80) 7 (70)
Pethidine 0 1 (10)
Morphine+parecoxib 2 (20) 2 (20)
Dose of morphine (mg) 32.0 ± 17.1 16.4 ± 12.7
Median (range) 32 (10–64) 12 (6–44)
Operation time (hr) 3.0 ± 1.1 2.7 ± 1.2
Blood loss (mL), 200 (100–500) 100 (100–300)
median (range)
Serum potassium 3.83 ± 0.31 3.78 ± 0.44
(mmol/L)
*Data are presented as mean ± standard deviation or n (%).
Treatments of potential value that can be practically
and easily applied for almost all patients include intra-
venous cisapride, gum chewing and laxatives. Cisapride, 
a prokinetic drug, administered intravenously to patients
undergoing colon surgery has been shown to significantly
reduce hospital stay,2,15 but because of serious adverse
cardiovascular effects, it must be used with extreme 
caution.18 Gum chewing has been investigated in three
randomized controlled trials enrolling patients undergo-
ing colon surgery. Two studies reported no beneficial
effects4,13 while one reported a significant reduction in
the length of hospital stay.12 These results are therefore
not conclusive, but gum chewing also requires some
effort on the part of the patient. Laxatives have been 
studied in a non-randomized study in patients under-
going radical hysterectomy.5 Both orally administered 
milk of magnesia and bisacolic suppository were used.
Significantly earlier return of bowel function and earlier
hospital discharge were observed compared with histor-
ical controls. To our knowledge, no randomized con-
trolled trials have been conducted to address the benefit
of rectally administered laxatives in resolving postopera-
tive ileus.
In theory, the use of suppository laxatives to stimulate
bowel activity should be a good method to hasten the reso-
lution of postoperative ileus, especially after colon surgery.1
The laxative action of rectally administered bisacodyl is
almost entirely local, with very little absorption,19 making
this drug quite safe to use in this manner. Using rectal sup-
positories does not require active participation or effort
on the part of the patient, unlike sham feeding methods
such as gum chewing. The fear that a vigorous stimula-
tion of the bowel might cause anastomotic dehiscence is
probably unfounded as the use of good surgical technique
and appropriate suture materials should make the anasto-
mosis resistant to such problems.
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Table 2. Outcome variables in the control (n = 10) and treatment (n = 10) groups*
Baseline variables
Control group Treatment group 
p
n (%) n (%)
Time to audible bowel sounds 0.051†
Day 1 0 2 (20)
Day 2 8 (80) 8 (80)
Day 3 2 (20) 0
Timing of flatus 0.121‡
Day 3 or before 6 (60) 9 (90)
After Day 3 4 (40) 1 (10)
Time to defaecation < 0.001†
Day 3 2 (20) 10 (100)
Day 4 5 (50) 0
Day 5 3 (30) 0
Time to oral intake 0.674†
Day 4 0 3 (30)
Day 5 3 (30) 0
Day 6 7 (70) 7 (70)
Number of suppositories 0.002‡
One tablet 2 (20) 9 (90)
Two tablets 8 (80) 1 (10)
Postoperative complications 0.136‡
No 8 (80) 10 (100)
Yes (surgical site infection) 2 (20) 0
Length of hospital stay (d) 10.4 ± 5.2 8.5 ± 2.7 0.325§
Median (range) 8 (7–24) 8 (6–15) 0.240†
*Data are presented as n (%) or mean ± standard deviation; †Wilcoxon rank sum test; ‡χ2 test; §t test.
The small sample size in this study precluded a more
definite statement on whether the use of bisacodyl sup-
pository can reduce hospital stay, and hence hospital
costs. Similarly, the absence of any anastomotic complica-
tion might also be attributed to the small sample size. The
large difference in the amount of opioids used between the
two groups in the study is of some concern, but unlikely
to explain away all the effects of bisacodyl on the outcomes.
The inclusion of laparoscopic-assisted colorectal proce-
dures might have diluted the difference between the two
groups, but apparently not enough to affect statistical sig-
nificance. The selection of colon cancer patients and colonic
procedures might not allow generalization to patients oper-
ated on for upper gastrointestinal tract diseases. Larger
studies are needed to confirm the findings presented in this
study, especially the trend in decreasing hospital stay.
In conclusion, bisacodyl suppository seems to be
effective in resolving postoperative ileus in colon cancer
patients undergoing elective colon resection and may
decrease the length of hospital stay without increasing
the risk of postoperative complications.
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